A Study of T-DXd in Patients with Selected HER2-overexpressing Tumors

Study identifier:D781AC00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Patients with Selected HER2-overexpressing Tumors (DESTINY PanTumor03)

Medical condition

Advanced solid tumors (excluding gastric cancer and breast cancer)

Phase

Phase 2

Healthy volunteers

No

Study drug

Trastuzumab deruxtecan

Sex

All

Estimated Enrollment

50

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 14 Mar 2024
Estimated Primary Completion Date: 30 Oct 2025
Estimated Study Completion Date: 14 Apr 2026

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Daiichi Sankyo Co., Ltd.

Inclusion and exclusion criteria